Tolerability of sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy and evaluation of the diagnostic accuracy of contrast-enhanced CT for lymph node metastasis

Tolerability of sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy and evaluation of the diagnostic accuracy of contrast-enhanced CT for lymph node metastasis - Sentinel lymph node biopsy after neoadjuvant therapy in node-positive breast cancer and evaluation of the diagnostic accuracy of contrast-enhanced CT

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059734

Enrollment

Registered

2025-11-11

Start date

2021-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Sentinel lymph node biopsy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aquired clinical node negative breast cancer after neoadjuvant therapy

Exclusion criteria

Exclusion criteria: Inoperable case Inflammatory breast cancer

Design outcomes

Primary

Measure	Time frame
5-year axillary lymph node relapse free survival	—

Secondary

Measure	Time frame
Concordance rate between our department's axillary lymph node metastasis diagnostic criteria on contrast-enhanced CT and pathological lymph node metastasis Diagnostic potential of SNB Axillary lymph node recurrence rate 5-year disease-free and overall survival Rate of arm lymphedema	—

Countries

Japan

Contacts

Public ContactYuri Tamura

Osaka City General Hospital Department of Breast Surgical Oncology

wbykk742@gmail.com06-6929-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026